AbbVie's ABBV-1088 trial halted before results

NCT ID NCT06579300

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a Phase 1 study to check the safety and how the body processes ABBV-1088 in healthy adults, including Western, Han-Chinese, and Japanese participants. It also looked at how ABBV-1088 interacts with another drug, itraconazole. The study was terminated early, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ABBV-1088

What could go wrong

This trial was terminated early, so no data on safety or effectiveness were collected. It is a very early Phase 1 study in healthy volunteers, not patients, so it cannot show any treatment benefit.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Acpru /Id# 270552

    Grayslake, Illinois, 60030, United States

  • CenExel ACT- Anaheim Clinical Trials /ID# 276423

    Anaheim, California, 92801, United States